The problem with current weight loss drugsModern GLP-1 weight loss drugs have transformed obesity care, helping patients lose significant amounts of weight.
Research shows that a substantial portion of weight loss can come from lean mass, including muscle.
This has pushed scientists to look beyond simple weight loss and focus on body composition.
For instance, adding a muscle-preserving drug to a GLP-1 therapy has been shown to cut lean mass loss by roughly half while maintaining weight loss.
Losing too much muscle during weight loss can slow metabolism, increase the risk of regaining weight, and affect mobility, especially in older adults.
A new generation of weight loss drugs is aiming to target fat while preserving muscle, addressing one of the biggest concerns linked to popular GLP-1 treatments like Ozempic
The next chapter in weight loss drugs is not just about dropping kilos. It is about what kind of weight the body loses.
A new generation of experimental obesity drugs is now being designed to target fat specifically while preserving muscle, a shift that could redefine how doctors treat obesity and metabolic disease.
Early data suggests this approach may address one of the biggest concerns surrounding blockbuster treatments like GLP-1 drugs such as Ozempic and Mounjaro.
The problem with current weight loss drugs
Modern GLP-1 weight loss drugs have transformed obesity care, helping patients lose significant amounts of weight. But they are not perfect.
Research shows that a substantial portion of weight loss can come from lean mass, including muscle. In some studies, around 25 to 40 per cent of total weight lost has been linked to lean tissue.
Advertisement
That matters because muscle is not just about strength. It plays a central role in metabolism, blood sugar control, and long-term weight maintenance.
This has pushed scientists to look beyond simple weight loss and focus on body composition.
A shift towards fat-specific weight loss
Instead of merely suppressing appetite, newer therapies are being designed to influence how the body uses and stores energy.
The goal of these next-generation obesity treatments is to reduce visceral fat around organs, improve metabolic health, and preserve or even protect lean muscle mass.
More from Lifestyle More from Lifestyle
This represents a major shift from “eat less, weigh less” to a more targeted approach of “lose fat, keep muscle”.
Survodutide: The drug leading the conversation
One of the most closely watched candidates is survodutide, an experimental injectable drug being developed for obesity and related conditions.
In a large late-stage clinical trial:
Patients lost up to 16.6 per cent of body weight over 76 weeks
Visceral fat fell by up to 34 per cent
Liver fat dropped by over 60 per cent
Most of the weight loss came from fat rather than muscle
Further analysis showed that lean mass made up only a small proportion of the weight lost, suggesting the drug may preserve muscle while targeting harmful fat.
This is significant because visceral and liver fat are strongly linked to conditions such as type 2 diabetes and fatty liver disease.
Not a replacement, but an evolution
Despite the excitement, experts are not calling time on Ozempic or similar drugs.
Advertisement
Instead, the future may involve combination therapies, where GLP-1 drugs reduce appetite and new agents help protect muscle or boost fat burning.
Some early studies are already exploring this approach. For instance, adding a muscle-preserving drug to a GLP-1 therapy has been shown to cut lean mass loss by roughly half while maintaining weight loss.
Why muscle preservation matters
The focus on muscle is not cosmetic. It is medical.
Losing too much muscle during weight loss can slow metabolism, increase the risk of regaining weight, and affect mobility, especially in older adults.
That is why researchers are increasingly treating obesity as a condition of metabolic health, not just body weight.
A rapidly evolving field
The anti-obesity drug market is expanding quickly, with multiple pharmaceutical companies racing to develop treatments that are more effective, easier to take, and better at preserving muscle.
Newer drugs in development are aiming for higher fat loss percentages and improved overall health outcomes, signalling a competitive and fast-moving landscape.
